Liaison(s): Bonnie Vlahos, Paul Sanders, Carol Bergey
Pfizer is a leading company in research and development to work on the translation of science into therapies for patients in need. This corporation is a key contributor to the rapidly changing global community and building partnerships for the evolving needs of society. The corporate responsibility is to strengthen health systems, increase access to developing medicines, and find sustainable solutions to the health challenges of today, and tomorrow. The company focuses its resources in disease areas with the best commercial success such as inflammation and immunology. The company has a long commitment to this therapeutic area and holds a wide variety of immuno-inflammation potential therapies. The partnership between Keck Graduate Institute and Pfizer is to expand on the Phase 3 clinical program planning evaluating inflammatory skin conditions. The current industry demand is to provide patients, providers, and payers with new medicines to address unmet medical needs more efficiently using innovative methods to accelerate clinical development programs. To meet the demand, the team masters project team identified innovative solutions to streamline the clinical development plan for a novel topical treatment. The first line therapy for the treatment of inflammatory skin conditions is topicals. The projected clinical development plan has two main deliverables. The first was to identify innovative digital technologies to increase efficiency and decrease cycle time. The objective was to maintain costs, improve patient experience, gain regulatory approval, and launch products quicker. The second was to integrate implementation steps in a detailed project plan and develop an organized literature repository.